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Abstract
Background: Tau pathology in AD spreads in a hierarchical pattern, whereby it first appears in the entorhinal
cortex, then spreads to the hippocampus and later to the surrounding areas. Based on this sequential appearance,
AD can be classified into six stages (“Braak stages”). The mechanisms and agents underlying the progression of
Tau pathology are a matter of debate. Emerging evidence indicates that the propagation of Tau pathology may
be due to the transmission of Tau protein, but the underlying pathways and Tau species are not well understood.
In this study we investigated the question of Tau spreading via small extracellular vesicles called exosomes.
Methods: Exosomes from different sources were analyzed by biochemical methods and electron microscopy (EM)
and cryo-EM. Microfluidic devices that allow the culture of cell populations in different compartments were used to
investigate the spreading of Tau.
Results: We show that Tau protein is released by cultured primary neurons or by N2a cells overexpressing different
Tau constructs via exosomes. Neuron-derived exosomal Tau is hypo-phosphorylated, compared with cytosolic Tau.
Depolarization of neurons promotes release of Tau-containing exosomes, highlighting the importance of neuronal activity.
Using microfluidic devices we show that exosomes mediate trans-neuronal transfer of Tau depending on synaptic
connectivity. Tau spreading is achieved by direct transmission of exosomes between neurons. In organotypic hippocampal
slices, Tau-containing exosomes in conditioned medium are taken up by neurons and microglia, not astrocytes. In N2a cells,
Tau assemblies are released via exosomes. They can induce inclusions of other Tau molecules in N2a cells expressing mutant
human Tau. We also studied exosomes from cerebrospinal fluid in AD and control subjects containing monomeric and
oligomeric Tau. Split-luciferase complementation reveals that exosomes from CSF can promote Tau aggregation in
cultured cells.
Conclusion: Our study demonstrates that exosomes contribute to trans-synaptic Tau transmission, and thus offer new
approches to control the spreading of pathology in AD and other tauopathies.
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Background
Tau aggregates are one of the hallmarks of Alzheimer
disease (AD) [1]. In AD, the distribution of Tau aggregates
correlates with the severity of dementia and occurs in a hier-
archical pattern, whereby it first appears in the entorhinal
cortex, then spreads to the hippocampus and later to the
surrounding areas [2]. Based on this sequential appearance,
AD can be classified into 6 stages [3]. Up to date, the mech-
anism underlying the progression of Tau pathology remains
elusive. It has become of major interest, as blocking the
propagation of Tau pathology might represent a promising
therapeutic strategy for AD and other tauopathies.
In AD, neurons prone to develop NFTs are projection
neurons with long axons that are only poorly myelinated
[4]. This led to the assumption that these neurons are
intrinsically vulnerable to Tau pathology, because they
have high energy requirements (that is, high metabolic
rates) that may subject them to chronic oxidative stress
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[5]. In addition their poor myelination increases their
exposure to toxic environmental conditions, as myelin
sheaths provide a mechanical barrier against pathogens
and provide trophic support and protection against oxi-
dative stress [6]. On the other hand, neurons affected by
Tau pathology appear to be anatomically connected [7].
Thus, it is not clear whether the spread of Tau pathology
is due to their neuronal connectivity or due to the differ-
ential vulnerability of neurons to Tau pathology. Emer-
ging evidence supports the former proposal. Several
recent studies showed that inoculation of Tau aggregates
induces time-dependent spreading of Tau pathology
from the inoculation site to synaptically connected brain
regions in human Tau transgenic mice or even in wild
type mice. In two lines of Tau transgenic mice, the ex-
pression of human Tau under the control of the neurop-
sin promoter was restricted to the entorhinal cortex, yet
Tau aggregates composed of transgenic human Tau and
endogenous mouse Tau were detected in brain regions
downstream in the synaptic circuit such as the dentate
gyrus, CA fields of the hippocampus, and cingulate
cortex [8, 9]. Since no expression of human Tau was
detected in these regions, human Tau in these areas
should derive from the entorhinal cortex. Taken to-
gether, these studies indicate that Tau may be transmit-
ted between neurons by a trans-synaptic pattern.
However, the mechanism of transmission remains a
matter of debate.
Tau is a microtubule associated protein and as such is
primarily an intracellular protein. However, several recent
studies showed that Tau can be physiologically released to
the extracellular fluid both in vivo and in cultured cells,
and such release appears to be regulated by neuronal ac-
tivity [10–13]. So far, the physiological function of extra-
cellular Tau remains elusive. In vitro and in vivo studies
showed that exogenous Tau aggregates can be internalized
by neurons and act as seeds to induce the aggregation of
other Tau proteins [14–17]. Based on these findings, it has
been proposed that the release and uptake of Tau under-
lies the spreading of Tau pathology [18]. However, how
and what Tau species are released by donor neurons and
then taken up by recipient neurons is not clear.
Exosomes are small extracellular vesicles with a diam-
eter of 50–150 nm, which derive from multivesicular
endosomes fusing with the plasma membrane [19, 20].
Secreted exosomes can be taken up by and thus deliver
their content to the recipient cells [21] thus representing
a novel intercellular communication pathway. Exosomes
can be released at neuronal presynaptic terminals and
taken up by postsynapses at Drosophila neuromuscular
junctions (NMJ) [22], and therefore qualify as carriers
for trans-synaptic transmission of proteins. Therefore, it
is reasonable to assume that exosomes might be in-
volved in the trans-synaptic spreading of Tau pathology.
It has been reported that α-synuclein, prion protein and
β-amyloid are present in exosomes [23–25], but whether
or not Tau is a component of exosomes is still a matter
of debate. Several studies showed that exosomes isolated
from the conditioned medium of cultured cell lines
over-expressing Tau or CSF from AD patients indeed
contain Tau [26–28], while other studies reported that
no Tau was detected in exosomes isolated from condi-
tioned medium of cultured primary neurons or cell lines
[12, 29]. Thus, more investigation is needed to clarify
this issue.
In the current study, we determined that Tau is a
bona fide component of exosomes. We characterized
the Tau species secreted in association with exosomes
from cultured neurons or human CSF from AD or
control subjects. Using microfluidic devices we showed
that exosomes play a role in the neuron-to-neuron
transmission of Tau. Finally, we found that exosomes




Mouse monoclonal antibodies against Alix/AIP1 and
Flotillin-1 were purchased from BD Biosciences (Heidelberg,
Germany). Rabbit polyclonal antibody K9JA was purchased
from Dako (Dako, Glostrup, Denmark). Phosphorylation-
dependent monoclonal mouse antibody PHF1 (against
pS396 + pS404) was a gift from Peter Davies (Albert Einstein
College, Bronx, NY, USA); 12E8 (against pS262 and pS356)
was from Peter Seubert (Elan Pharmaceuticals, South
San Francisco, CA, USA); AT8 (against pS202 + pT205)
and AT180 (against pT231) were from Pierce (Thermo,
Fisher Scientific, Bonn, Germany). Antibody against
GluR1 was purchased from Millipore (Darmstadt,
Germany). Thioflavine S and antibody against synaptophy-
sin was obtained from Sigma (Steinheim, Germany).
Cell culture, transfection and treatments
The inducible Tet-On mouse neuroblastoma cells (N2a)
expressing the 4-repeat domain of Tau or full-length Tau
harboring the FTDP-17 mutation ΔK280 was generated
as previously described [30]. The cells were cultured in
Eagle’s Minimum Essential Medium (MEM) supple-
mented with 10% exosome-depleted fetal bovine serum
(FBS), 0.1% nonessential amino acids, and 600 μg/ml G418.
The exosome-depleted FBS was prepared by centrifuga-
tion at 100,000 × g for 1 h. The expression of Tau was
induced with 1 μg/ml doxycycline.
Cortical neurons were isolated from Sprague-Dawley
rat embryos at Day 18 (E18) and seeded on poly-D-
lysine-coated (50 μg/mL) dishes. The cultures were kept
for 4 h in plating medium (MEM, 10% horse serum
albumin (no tau was detected in exosomes isolated from
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50 ml horse serum, data not shown), 1 mM pyruvic
acid, 0.6% glucose, 1× penicillin/streptavidin) and
then the medium was exchanged to NeuroBasal
medium supplemented with B27 (Invitrogen, Carlsbad,
CA, USA), L-Glutamine and Penicillin/Streptomycin.
Four days after seeding, cytosine arabinoside (Sigma,
Munich, Germany) was added to the conditional
medium at a final concentration of 5 μg/ml to inhibit
the glial proliferation.
For neuronal culture in microfluidic devices (Xona
microfluidics, USA), hippocampal neurons isolated from
Sprague-Dawley rat embryos at Day 18 (E18) were
seeded at a density of ~6 × 104 cells on one side (somal
side). Two weeks later, the other side of the microfluidic
devices (neuritic side) was seeded with hippocampal
neurons at a density of ~3 × 104 cells. The neurons were
cultured as described above.
When the neurons on the somal side of the micro-
fluidic devices reached the age of DIV18 or DIV25, 60 μl
of conditioned medium in each well on the somal side
was removed and then 10 μl of purified exosomes
re-suspended in conditioned medium was added to each
of the two wells for 24 h.
Transfections of N2a cells with GFP-Tau construct
(human Tau tagged with GFP at the N-terminus (longest
isoform in CNS, 2N4R or hTau40, for short TauGFP)) or
with GFP-Flotillin (FlotillinGFP) and the RFP-Tau con-
struct (human Tau tagged with RFP at the N-terminus
(longest isoform in CNS, 2N4R or hTau40, for short
TauRFP)) were performed with lipofectamine 2000 (Invi-
trogen) according to manufacturer’s manual. Twenty-
four hours later, the conditioned medium was removed,
and the cells were washed with warm PBS and split into
new flasks. Cortical neurons were infected with adeno-
virus expressing the same Tau construct tagged with
CFP at the N-terminus (TauCFP).
Cytotoxicity assay
Cytotoxicity was determined by a lactate dehydrogenase
(LDH) assay kit (Roche Applied Science, Indianapolis,
USA) according to manufacturer’s manual. Cell death
was calculated as percent of LDH released into the
medium, compared with total LDH obtained.
Organotypic hippocampal slice culture and treatments
Hippocampal organotypic slice cultures were prepared
from non-transgenic P8 mice and cultured as described
previously [31]. At 15 DIV, 200 μl of a GFP-hTau40-
exosome-preparation was applied to the medium of
organotypic slice cultures for 24 h at 37 °C/5%CO2 at-
mosphere. As a control, 200 μl of the same exosome
preparation was sonicated before application.
Purification of exosomes
Exosomes were purified from conditioned medium of
N2a cells or cultured cortical neurons (DIV14-21) as de-
scribed [32]. Briefly, conditioned medium was collected
from 10 to 16 dishes (150 mm) of neurons at a density
of 1.5 × 107 cells/dish or from nine T150 flasks of N2a
cells at a density of 2–2.5 × 107 cells/flask. The collected
medium was centrifuged at 300 × g for 10 min to remove
cells. The supernatant was then sequentially centrifuged
at 2000 × g for 10 min to remove dead cells and at
10,000 × g for 30 min to remove cell debris. Afterwards, the
supernatant was collected and centrifuged at 100,000 × g
for 70 min. The pellet (exosomes + contaminating proteins)
was washed with PBS to eliminate contaminated proteins
and centrifuged at 100,000 × g for 70 min to collect purified
exosomes. The exosomes were then used for treatment of
N2a cells or cultured primary neurons.
For sucrose gradient centrifugation, the 100,000 × g
pellet was resuspended in 2.5 M sucrose in 20 mM
Hepes (pH 7.4), and a step gradient of sucrose (2.25, 2.0,
1.75, 1.5, 1.25, 1.0, 0.75, 0.5, and 0.25 M) was layered
over the exosome-containing 2.5 M sucrose solution as
described [24]. The gradient was spun at 100,000 × g for
18 h. Fractions were collected from the bottom of the
gradient, diluted with PBS, and spun at 100,000 × g for 2 h.
The pelleted fractions were then used for immunoblotting.
The sonication of exosomes was done with a Sonoplus
Ultrasonic homogenizer (Bandelin, Berlin, Germany)
using 20% amplitude for 10s.
Human CSF collection
Lumbar CSF of patients with AD and from psychiatric
controls was collected with an atraumatic needle at the
Department of Psychiatry, University Medical Center,
Göttingen, Germany after written informed consent was
obtained (IRB 02/05/09). All performed analyses with
human CSF were approved by the ethics committee of
the Medical Faculty, University Medicine Göttingen (IRB
02/05/09). Specimens were collected in polypropylene
tubes and centrifuged at 2,000xg for 10 min at room
temperature, aliquoted and frozen at −80 °C within
30 min of the procedure’s completion.
All AD patients fulfilled the NINCDS-ADRDA diagno-
sis criteria for probable AD [33]. Patients were exten-
sively characterized by the memory clinic’s expert
physicians and neuropsychologists including physical,
neurological, psychiatric and neuropsychological exam-
ination, brain imaging as well as CSF Abeta 42, Tau and
phospho-Tau analysis. Controls included CSF from
patients with different psychiatric diagnoses (overview in
Tables 1 and 2). None of the control patients suffered
from neurodegenerative disorders or dementia. Only
CSF samples with normal routine parameters were used.
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Purification of extracellular vesicles (EVs) from CSF
EVs were isolated as described previously [23, 34]. In
brief, 2 ml of CSF were subjected to subsequent centri-
fugation steps performed at 4 °C, 3,500 × g for 10 min, 2
times 4500 × g for 10 min, 10,000 × g for 30 min and
100,000 × g for 60 min. The 100,000 × g pellet was
washed once with PBS and then re-suspended in PBS.
Nanoparticle tracking analysis (NTA)
NTA was performed with a NanoSight NS300 (NanoSight
Ltd., Amesbury, UK) or a Zetaview instrument (Particle-
Metrix Ltd., Meerbusch, Germany). The purified exosomes
were diluted 1:100–1:500 (conditioned cell medium) or 1:4
in PBS and subjected to NTA. Samples were measured in
triplicates. Particle numbers were analyzed with the
Nanoparticle Tracking Analysis (NTA) 3.0 software (for
Nanosight NS300) or with the Zetaview 8.02.30.02.
Flow cytometry
Flow cytometry were performed on a Gallios flow cyt-
ometer (Beckman Coulter) equipped with a 22 mW
blue laser operating at 488 nm. The enhanced wide
forward scatter detector mode (1–19° angles with log
amplification) was used to detect the microparticles in
conditioned medium. Thirty microliter of conditioned
medium containing exosomes was diluted into 1 ml
with PBS and then measured on the FITC channel with
a flow-rate of 30 μl/min. The instrument was allowed
to count to a maximum of 20,000 events or 300 s,
whichever was earlier without gating.
Atomic force microscopy (AFM)
The exosomal samples were diluted in PBS, and then
loaded on the freshly cleaved mica for 15 min, followed
by rinsing in imaging buffer (10 mm Tris-HCl, pH 7.4,
50 mm KCl). AFM imaging was performed in oscillation
mode using a Nano Wizard Ultra-speed AFM micro-
scope (JPK instruments) and Si3N4 cantilevers (NPS
series, Bruker) with spring constants of 0.1–0.6 N/m. To
achieve minimal imaging forces between AFM stylus
and sample, the drive amplitude was set between 0.5 and
1.0 V, and the amplitude set point was adjusted manually
to compensate for the thermal drift of the AFM. The ac-
quired images were processed using JPK data processing
Table 1 CSF samples from AD patients or control patients with
different psychiatric diagnoses used in western blot analysis
Patients Diagnosis Gender Age
502 schizophrenia m 32
508 alcohol addiction, depression m 54
511 alcohol addiction, depression m 49
513 depression m 60
519 depression m 47
528 schizophrenia m 48
534 schizophrenia f 46
542 schizophrenia f 63
549 depression f 44
562 depression f 55
385 AD m 82
395 AD f 77
401 AD f 66
402 AD m 75
540 AD m 78
545 AD f 77
550 AD f 69
553 AD f 81
554 AD m 74
555 AD f 87
Table 2 CSF samples from AD patients or control patients with
different psychiatric diagnoses used in luciferase protein-fragment
complementation assay
Patients Diagnosis Gender Age
106 multiple sclerosis m 57
233 bipolar disorder f 55
242 seizures f 70
246 major depression m 41
253 pseudotumor cerebri f 46
254 subdural hematoma m 70
262 alcohol addiction f 51
270 bipolar disorder m 59
271 major depression f 51
273 schizophrenia f 44
276 ketoacidotic coma, personality change
after recurrent ketoacidotic coma
f 53
281 opiate addiction f 48
308 vascular dementia f 63
299 AD f 74
322 AD f 62
332 AD m 78
337 AD m 79
383 AD m 80
401 AD f 65
415 AD f 67
449 AD m 53
463 AD m 79
548 AD m 73
553 AD f 80
585 AD f 76
647 AD f 64
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software. The height analysis was performed using the
cross section method in the JPK software.
Transmission (Cryo-) electron microscopy and tomography
Transmission electron microscopy (TEM) was done as
described previously [32]. In brief, exosomes derived from
N2a cells or cortical neurons were fixed with 2% PFA and
incubated for 20 min on carbon/formvar coated 200 meshes
grids. The grids were then washed with PBS for 3 times and
treated with 1% glutaraldehyde for 5 min. Afterwards, the
grids were embedded in 2% methylcellulose; negative
stained with 2% uranyl acetate and analyzed with a Philips
CM12 electron microscope (Amsterdam, Netherlands).
For cryo-EM, exosomes were vitrified by plunge freezing
(Leica EM GP). In brief, exosomes derived from N2a-cells
(expressing TauRDΔK280 or TauGFP) or derived from
neuronal cells were loaded onto holey carbon grids
(200 mesh, Quantifoil, Germany), followed by plunge-freezing
at 95% humidity and 25 °C. The state of vitreous water in the
frozen samples was verified by electron diffraction.
Cryo-electron tomograms were recorded using a JEOL
JEM2200 FS (Figs. 4 and 7) and a FEI Titan Krios (Fig. 1)
cryo-Transmission electron microscope at low dose
conditions. Tomograms were recorded at magnifications of
14,000x (FEI) and 20,000x (JEOL) corresponding to pixel
sizes of 0.5 nm at specimen level, with a defocus of −4 to
−6 nm. Samples were tilted from −60 to +60 with tilt
increments of 2 or 3° steps, resulting at a total dose of
60–70 e/Å2. Tomograms were recorded using serialEM
[35, 36]. Tomograms were aligned with respect to a
common origin using cross-correlation techniques using
the software IMOD [37]. Reconstructions were generated
using the Simultaneous Iterative Reconstruction Technique
(SIRT) algorithms, and isosurface visualization was per-
formed by the 3dmod software which is part of the IMOD
software suite.
Proteinase K protection assay and high salt treatment
of exosomes
The neuron-derived exosomes were divided into 30 μl
aliquots and then were either left untreated or treated
with 1% saponin, 50 ng proteinase K (prot K) or 50 ng
proteinase K together with 1% saponin. The samples
were incubated for 5 min or 1 h at 37 °C. SDS loading
buffer was then added and the samples were heated at
95 °C for 5 min and analyzed by western blotting.
To dissociate extra-vesicle Tau in association with
exosomal surface, the neuron-derived exosomes were
incubated with increasing amounts of NaCl (0 M,
0.01 M, 0.1 M, 0.25 M or 0.5 M). Afterwards, exosomes
were collected by centrifugation at 100,000 × g, 4 °C
for 70 min, then resuspended in SDS loading buffer.
The samples were heated to 95 °C for 5 min and ana-
lyzed by western blotting.
Luciferase protein-fragment complementation assay
Complementation pairs of TauRDΔK-N terminus of lucifer-
ase and TauRDΔK –C terminus of Luciferase were trans-
fected into N2a cells in a T25 flask as described above.
Three hours after transfection the cells were washed, trypsi-
nated and placed into 96-well plates at a density of 15,000
cells/well. One hour later, the cells were treated with exo-
somes from human CSF or PBS. Forty-eight hours after
treatment, the cells were treated with luciferin for 10 min
and then subjected to luciferase activity measurement using
an Ivis Lumina II system (Caliper Life Science).
Immunofluorescence
N2a cells were fixed with 3.7% paraformaldehyde in
phosphate buffered saline (PBS) for 15 min at room
temperature and then permeabilized with 80% methanol
for 6 min at −20 °C. Thioflavine S staining and labeling
of Tau was done as described previously [38]. For optical
analysis a confocal microscope was used (LSM510, Zeiss,
Oberkochen, Germany).
For immunofluorescence of neurons cultured in micro-
fluidic devices, after treatment with exosomes, the cham-
bers were removed and the neurons were fixed with 3.7%
Formaldehyde (Sigma)/4% Sucrose in PBS for 30 min at
37 °C. After washing with PBS three times, the cells were
permeabilized with 0.1% Triton X-100 for 10 min at room
temperature and then blocked in 5% bovine serum albu-
min (BSA) for 1 h at room temperature, followed by
incubation with the primary and secondary antibodies.
Confocal images were captured with a LSM700 micro-
scope (Zeiss, Oberkochen, Germany).
Organotypic hippocampal slice cultures were attached
on the Millicell membrane and stained as free-floating
sections in 6-well plates. Cultures were first fixed with
3.7% paraformaldehyde in PBS for 2 h at 4 °C. After wash-
ing with PBS, slices were permeabilized with 0.1%
TritonX-100/PBS for 90 min at room temperature. Slices
were then blocked with 5% BSA for 2 h, followed by incu-
bation with primary antibodies diluted in PBS for 3 days
at 4 °C. After washing three times with PBS, slices were
incubated with secondary antibody for 3 days at 4 °C.
Afterwards, slices were washed three times with PBS
and then mounted with Permafluor mounting solution
(Beckman Coulter, Paris, France). The following primary
antibodies were used: microtubule associated protein 2a/b
(MAP2a/b) (Abcam, 1:1000)), GFAP (Sigma-Aldrich,
Germany; (1:1000)) and Iba1 (Wako, Japan 1:500). All
fluorescently labeled secondary antibodies were from
Dianova (Hamburg, Germany) (1:1000).
Enzyme-linked immunosorbent assay (ELISA)
The levels of Tau in neuron-derived exosomes and
conditioned medium of neuronal culture were deter-
mined by a commercially available validated ELISA kit







Fig. 1 (See legend on next page.)
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(Invitrogen, Carlsbad, CA, USA) according to the man-
ufacturer’s instructions. All the samples were treated
with 1% CHAPS detergent.
Biochemical analysis
After washing twice with cold PBS, neurons or N2a cells
were extracted with extraction buffer (50 mM Tris-HCl,
pH 7.5; 100 mM NaCl, 1% Triton X-100 supplemented
with phosphatase inhibitors and protease inhibitors).
Purified exosomes were extracted with extraction buffer.
Afterwards, the extracts were centrifuged at 4 °C at
16,000 × g for 20 min, and the supernatants were collected
for western blot analysis.
Soluble and insoluble Tau protein was separated by
sarkosyl extraction as described previously [38]. For
extraction of N2a cells, the sarkosyl-insoluble pellets
were suspended in sample buffer in 1/20 of the volume
of supernatants, and the sarkosyl insoluble pellets and
supernatants were loaded at 60:1 (pellet:supernatant)
for western blotting. For extraction of exosomes, the
sarkosyl-insoluble pellets were suspended in sample
buffer in 1/3 of the volume of supernatants, and the
sarkosyl insoluble pellets and supernatants were loaded
at 9:1 (pellet:supernatant) for western blotting. Electro-
phoresis and western blotting were done as described
previously [38]. For quantification of Tau levels, the
western blots were probed with the pan-Tau antibody
K9JA and analyzed by densitometry.
Statistical analysis
Statistical analysis was performed with the statistics soft-
ware Prism5 (GraphPad, La Jolla, CA, USA). Data was
analyzed either by Student’s t-test or One way ANOVA
followed by Tukey’s multiple repeat comparison (Statistica,
Statsoft (Europe), Hamburg, Germany) as indicated. Data
are shown as mean ± SD or mean ± SEM. p-values are as
follows:* < 0.05, ** < 0.01, *** < 0.001.
Results
The release of Tau via exosomes by cultured cortical
neurons
Primary neurons have been shown to release exosomes
[39] and recent studies demonstrated the secretion of
Tau by different cell lines and neurons [11, 12]. Thus we
sought to determine whether Tau protein can be
released via exosomes. It was reported that Tau was not
contained in exosomes secreted by immature cortical
neurons (DIV9) [29]. We confirmed this for exosomes
from young neurons (DIV 7-9) (data not shown) and
therefore we focused on exosomes released by mature
neurons (DIV14-21).
Exosomes in the conditioned medium of the cultured
cortical neurons (DIV14-21) were isolated according to a
published protocol [32] and lysed for western blot analysis.
The isolated exosomes were enriched for Alix and Flotil-
lin— two well-accepted exosomal markers, as much higher
amounts of these two proteins were detected in the exoso-
mal lysates than in the cell lysates (Fig. 1a, lanes 3, 4). Tau
was detected in exosomal lysates (Fig. 1a, lane 2), but,
unlike Alix and Flotillin, Tau was not a major protein com-
ponent of exosomes, since its level in exosomal lysates was
dramatically lower than that in cell lysates (about 14 fold
change, Fig. 1a, lanes 1, 2). The two Tau bands (Mr ~ 48
and 50kD) in the exosomal lysates were ~ 5kD smaller
than the Tau bands (Mr ~ 54 and 56kD) in the cell lysates
on SDS gels (Fig. 1a, lanes 1, 2). We suspected that this
might be due to the cleavage of Tau at Asp421 by caspase 3
because such a truncation generates a Tau fragment ~ 5kD
(See figure on previous page.)
Fig. 1 Release of Tau via exosomes by cultured rat cortical neurons. Conditioned medium of cortical neurons (DIV14-21) was collected for
isolation of exosomes. N denotes neuronal lysates, E exosomal lysates. a Western blot analysis of the distribution of neuronal Tau (left panel, lanes
1, 2) and exosomal markers (Flotillin and Alix, right panel, lanes 3, 4) in neuronal lysates and exosomes. Note: (1) Tau typically appears as two
bands, a weaker upper band at Mr ~56kD and a stronger lower band at Mr ~54kD (lane 1). (2) The Tau bands in exosomes have a lower Mr (~50kD
and 48 kD) than endogenous rat Tau bands. (3) Less Tau was detected in exosomes than in cell lysates, which is in contrast to Flotillin and Alix,
indicating Tau is not a major component of exosomes. b Quantification of Tau in exosomes and in conditioned medium of neuron culture using
ELISA. The conditioned medium from neuron culture (DIV17) was depleted of cells and cell debris via sequential centrifugation at 300 × g, 2000 ×
g for 10 min and 10,000 × g for 30 min. Tau in conditioned medium represents the total extracellular Tau and was used for calculation of the
percentage of exosomal and Non-exosomal Tau. c Exosomal Tau is intact and hypophosphorylated: To compare the phosphorylation status of Tau in
neuronal lysates and exosomes, neuronal lysates (lane 1) were dephosphorylated with alkaline phosphatase for 30 min at 37 °C (lane 2). This
lowers the Mr to the same level as exosomal Tau (lane 3), indicating that the change is due to phosphorylation and not due to truncation.
Exosomal Tau is recognized by antibody SA4470 against aa.1-17 of Tau and antibody Tau C-ter against aa.400-441 of Tau (2nd and 3rd panels),
indicating that both neuronal and exosomal Tau are intact. d Nanoparticle tracking analysis (NTA) of isolated exosomes showing
particle number vs. size (arbitrary units, peak = 100%). The distribution peaks at a diameter of ~75 nm, which is typical for exosomes. e Isolated
exosomes separated by sucrose gradient centrifugation. Neuronal lysates (N) and exosomal lysates (E) were loaded for comparison. Note: (1)
Tau is enriched in fractions 7 and 8 coincident with the exosomal markers Flotillin and Alix; (2) the Mr values of Tau bands in exosomes are
lower than those of endogenous rat Tau bands due to lower phosphorylation, which is consistent with the results shown in A. f Negative
stain-electron microscopy of isolated exosomes. Many exosomes appear as cup-shaped vesicles with diameters of 40–100 nm. Scale bar = 70 nm.
g Cryo-electron tomography of isolated exosomes. Because of the better preservation, exosomes reveal a more native spheroidal shape. The upper
panel (overview) shows that most exosomes (arrows) exhibit a size of 50–100 nm. For one selected exosome we show here (lower panel) an isosurface
representation of the membrane to visualize the outer shape of the vesicle
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smaller than intact Tau [40]. Thus, exosomal Tau was
analyzed with an antibody specific for Tau truncated at
Asp421, but no signal was detected (data not shown), sug-
gesting that exosomal Tau is not truncated at this site. We
quantified Tau in exosomes and in conditioned medium by
ELISA. We found that the exosomal Tau accounts for ~2%
of the total extracellular Tau (Fig. 1b), consistent with a
previous report (~3% of extracellular Tau) [41].
It has been reported that Tau released by cultured
neurons is hypophosphorylated [11]. This prompted us
to test whether exosomal Tau is also hypophosphory-
lated and thereby exhibits increased mobility on SDS
gels compared to the cytosolic Tau. We examined the
phosphorylation status of Tau with phosphorylation-
dependent antibody PHF1 and AT8. In addition, we
checked if dephosphorylation of neuronal Tau can
reduce the Mr difference between neuronal and exo-
somal Tau. We treated neuronal lysates with alkaline
phosphatase (AP) which resulted in a downward Mr
shift of ~5kD (Fig. 1c, 1st panel, lanes 1, 2), to a simi-
lar level as exosomal Tau bands (Fig. 1c, 1st panel,
lanes 2, 3). The loss of phosphorylation was con-
firmed by the disappearance of the PHF1 and AT8 re-
activity (Additional file 1: Figure S1, lanes 1, 2 and 4, 5).
Notably, PHF1 and AT8 did not detect Tau bands in
exosomal lysates (Additional file 1: Figure S1, lanes 3, 6),
indicating that they were not phosphorylated at these sites.
Collectively, these results show that exosomal Tau is in a
low state of phosphorylation compared to neuronal
cytoplasmic Tau.
To further confirm that exosomal Tau is intact but not
truncated, we probed Tau with antibody SA4470 (against
N-terminal residues 1–17) and with antibody Tau C-
ter (against C-terminal residues 400–441) (Fig. 1c,
panel 2, 3). Both antibodies recognized exosomal Tau
(Fig. 1c, lanes 6, 9), indicating that it is indeed intact.
To characterize the purified neuronal exosomes, we
examined the size distribution using nanoparticle track-
ing analysis (NTA). The size distribution peaked around
75 nm (Fig. 1d), which is typical for exosomes, indicating
their enrichment in the preparations. Another character-
istic feature of exosomes is their density, ranging from
1.08 to 1.22 g/ml depending on their cellular origin [32].
We fractionated exosomes on a sucrose gradient and
examined the distribution of the exosomal markers
Flotillin and Alix by western blotting. Both markers were
enriched in fractions 5–8 at a density between ~1.16
to ~1.06 g/ml (Fig. 1e, upper panels), which fits well
with the density of exosomes. Tau was enriched in
fractions 7 and 8 overlapping with Flotillin and Alix
(Fig. 1e, bottom panels), suggesting that the majority of
Tau is associated with exosomes in these preparations. We
assessed the morphology of the purified exosomes using
electron microscopy and atomic force microscopy. EM
showed that the vesicles were cup-shaped with a diam-
eter of ~40–100 nm (Fig. 1f ), consistent with the
typical exosomal morphology [32]. AFM confirmed that
the majority of the vesicles have diameters around 40–
100 nm (Additional file 2: Figure S2). The vesicles
exhibited disk-like structures, which is consistent with
exosomal morphology reported by other groups [42].
We further analyzed isolated exosomes using cryo-
electron tomography, which is known to preserve struc-
tures faithfully. This showed that vesicles exhibited a
roughly spheroidal shape with diameters of 50 - 100 nm
(Fig. 1g), which was in line with exosomal morphology.
Collectively, these results demonstrate that Tau can be
secreted by neurons via exosomes.
Upregulation of exosomal Tau release by neuronal activity
It has recently been reported that the release of en-
dogenous Tau via non-exosomal pathways by primary
neurons is a physiological process which is stimulated by
neuronal activity [11]. Interestingly, the release of exo-
somes by neurons is stimulated by neuronal activity as
well [39]. Thus, we examined whether stimulating neu-
rons could lead to elevated release of exosomal Tau.
Cultured neurons were depolarized with 25 mM KCl for
3 h, while the control cultures were incubated in the
same medium containing only 5 mM KCl. We first
examined whether depolarization of neurons caused
neurotoxicity using the LDH release assay. The high KCl
treatment did not increase LDH release (Fig. 2a),
suggesting that the depolarization of neurons within the
treatment timeframe was not neurotoxic. Next, we
checked the amount of Tau and Alix in lysates of these
neuronal cultures or exosomes derived from them. In
the neuronal lysates, depolarization of neurons did not
affect the levels of Tau and Alix (Fig. 2b, lanes 1, 2;
Fig. 2c). However, in the exosomal lysates, depolarization
of neurons increased both Tau and Alix levels by ~60%
(Fig. 2b, lanes 3, 4; Fig. 2d). Since the elevation of Tau
was proportional to the elevation of Alix (Fig. 2d), the
increase of Tau in exosomal preparations can be taken
to result from the increased release of exosomes, instead
of selective accumulation of Tau in exosomes. In conclu-
sion, chemical stimulation of neurons increases exoso-
mal secretion, leading to higher release of exosomal Tau.
Tau is located inside exosomes
Although a fraction of extracellular Tau is released via
exosomes, there is the question of its origin and top-
ology with regard to the exosomal vesicles. For example,
since some neuronal death occurs spontaneously during
culturing, a concern is whether the exosomal Tau is in
fact derived from dead neurons and only loosely
attached to the exosomal surface. To clarify this, we
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treated neuron-derived exosomes with increasing
amounts of NaCl (from 0.01 to 0.5 M) to detach Tau
stuck on the exosomal outer membrane and checked its
influence on Tau and exosomal markers Alix and
HSC70 [43]. NaCl treatment had little effect on levels of
Alix and HSC70 (Fig. 3a, lower panels), nor on exosomal
Tau (Fig. 3a, upper panel). This shows that Tau is not
just loosely associated with the exosomal surface, but
rather is an integral part of the exosomal vesicle.
To corroborate this finding, we performed a protein-
ase K protection assay to examine whether Tau is
protected by the exosomal membrane. Saponin was used
to permeabilize exosomes. The exosomal Tau level was
unchanged by treatment with either saponin or protein-
ase K alone for 5 min (Fig. 3b, upper panel, lanes 1–3),
but it was dramatically reduced by ~70% by treatment
with proteinase K together with saponin that perme-
abilized exosomes (Fig. 3b, upper panel, lane 4). The
extended treatments with either saponin or proteinase K
alone for 1 h reduced exosomal Tau levels by ~50%
(Fig. 3b, upper panel, lane 5–7), probably because during





Fig. 2 Depolarization of neurons stimulates release of exosomes containing Tau. Cortical neurons were incubated in control medium or
depolarizing medium containing 25 mM KCl for 3 h. a Cytotoxicity analyzed with LDH release assay. KCl treatment does not cause cell death.
Error bars: SD; n = 3. Student t-test: n.s., not significant. b KCl treatment enhances exosomal Tau release. Neurons or exosomes isolated from
conditioned medium of control neurons (lanes 1, 3) or depolarized neurons (lanes 2, 4) were lysed for western blot analysis. KCl treatment
does not change Tau and Alix levels in neuronal cell lysates (compare lanes 1, 2), but increases both Tau and Alix in exosomes (compare lanes
3, 4). c, d Quantification of blots shown in B for Tau (upper panel) and the exosome marker Alix (bottom panel) in cell lysates (c) or exosomes
(d). Shown are the ratios of proteins in cell lysates or exosomes (KCl-induced vs. control). Note that upon neuronal activation by KCl, Tau or
Alix in exosomes increase by ~50% (d), whereas Tau or Alix in cell lysates does not change (c). Error bars: SD; n = 4. Student t-test: *p < 0.05;
n.s., not significant
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to the digestion of the released Tau by proteases attached
to the exosomal surface or proteinase K resp. Notably, the
treatment with saponin and proteinase K for 1 h resulted
in the complete digestion of Tau as no exosomal Tau was
detected (Fig. 3b, upper panel, lane 8). Collectively, these
data show that exosomal Tau is protected from digestion
by proteinase K, indicating Tau is located within exosomes.
Similarly, the bona fide intraluminal exosomal proteins
Alix and HSC70 were protected from proteinase K diges-
tion (Fig. 3b, middle and lower panels, lanes 3, 4, 7, 8).
Exosomes can mediate the neuron-to-neuron transmission
of Tau
Since endogenous Tau can be released via exosomes, we
next examined whether exosomes can act as carriers to
mediate the transmission of Tau between cells. In
order to directly monitor Tau-containing exosomes,
we prepared exosomes from N2a cells transiently
over-expressing human Tau tagged with GFP at the
N-terminus (longest isoform in CNS, 2N4R or hTau40,
for short TauGFP). Western blot analysis revealed that
only intact TauGFP but not truncated TauGFP was
detected in exosomal preparations (Fig. 4a, top panel),
suggesting that all GFP positive exosomes should
contain TauGFP. The TauGFP protein was confirmed by
an anti-GFP antibody (Fig. 4a, middle panel). The exo-
somal preparations were validated by the enrichment
of the exosomal marker Flotillin in comparison with
the cell lysates (Fig. 4a, bottom panel). Nanoparticle
tracking analysis showed that the exosome preparation
mainly contained vesicles with a diameter of ~55–80 nm
(typical for exosomes), indicating the enrichment of exo-
somes in the preparations (Fig. 4b). Cryo-electron tomog-
raphy revealed that the vesicles exhibited a spheroidal
shape with a diameter of 50 -100 nm (Fig. 4c), which is in
line with exosomal morphology.
To investigate the neuron-to-neuron transmission of
exosomal Tau, we took advantage of microfluidic de-
vices (MFD). They allow the culture of two populations
of neurons in two separate chambers connected by mi-
crogrooves, enabling the direct observation of the
transfer of exosomal Tau from neurons on one side
(somal side) to neurons on the other side (neuritic side)
(Additional file 3: Figure S3, B, D). They also enable the
selective treatment of cells on only one side by applying
fluidic isolation via maintaining a flow of medium be-
tween the two sides (Additional file 3: Figure S3, B, D).
One caveat is that the uptake of exosomes can occur
both at the somatodendritic and axonal compartments
of neurons [6]. Thus even though exosomes were added
to the somal side of the chamber, some neurons on the
neuritic side projecting through microgrooves might
obtain exosomes via direct axonal uptake, independently
of the transfer of exosomes from neurons seeded on the
somal side. To solve this issue, we seeded the 1st order
neurons on the somal side two weeks earlier than the
2nd order neurons on the neuritic side, anticipating that
the projections from the 1st order neurons occlude the
microgrooves and thus eliminate axons and dendrites
from the 2nd order neurons to project through micro-
grooves (Additional file 3: Figure S3). To test whether
indeed only the 1st order neurons project through
a b
Fig. 3 Tau is localized inside exosomes. a Neuron-derived exosomes were incubated with increasing concentrations of NaCl to detach proteins
peripherally attached to the membrane. Tau is detected with the pan-Tau antibody K9JA. HSC70 and Alix were examined as exosomal markers.
Lines on the right indicate Tau protein, Alix and HSC70. M.W. markers are shown on the left. Note that exosomal Tau levels are not changed by
NaCl treatment (lanes 1–5), similar to exosomal markers HSC70 and Alix, indicating that Tau is not peripherally attached to the exosomal membrane
surface. b Proteinase K protection assay. Neuron-derived exosomes treated with or without 50 ng proteinase K (Prot K) in the presence or absence of
1% saponin (Sapo) for 5 min or 1 h at 37 °C, followed by western blot analysis. Note that Tau is strongly reduced (5 min) or even absent (1 h)
in exosomes treated with both Prot K and Sapo, compared with treatment with Prot K alone, indicating that the exosomal membrane protects
Tau against Prot K digestion





Fig. 4 (See legend on next page.)
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microgrooves, we selectively stained either the 1st order
neurons on the somal side (Additional file 3: Figure S3, C)
or the 2nd order neurons on the neuritic side (Additional
file 3: Figure S3, A) with DiI and monitored the staining of
cells by live imaging. When the 2nd order neurons were
stained with DiI, the cell bodies of some of the 1st order
neurons on the somal side were also positive for DiI,
because their neurites projected through microgrooves
into the neuritic side (arrowhead in Additional file 3:
Figure S3, A). By contrast, when the 1st order neurons
were stained with DiI, no cell bodies of the 2nd order neu-
rons were positive for DiI, although neurites from the 1st
order neurons that projected through microgrooves into
the neuritic side were labeled by DiI (Additional file 3:
Figure S3, C). These results confirm that only the 1st
order neurons projected through microgrooves. Ac-
cordingly, when the 1st order neurons were treated
with TauGFP exosomes, any TauGFP found in the
neurites or cell bodies of the 2nd order neurons would
indicate its transmission from the 1st order neurons.
Treatment of the 1st order neurons on the somal side
at DIV25 with TauGFP exosomes resulted in the distribu-
tion of TauGFP puncta in microgrooves (Fig. 4d, left
panels), indicating the uptake of TauGFP exosomes by
the 1st order neurons on the somal side. In addition, in
~4% (4.3 ± 0.4%) of the 2nd order neurons (DIV11), the
diffuse distribution of TauGFP and the accumulation of
TauGFP puncta in cell bodies was observed (Fig. 4d, right
panels), suggesting the transmission of TauGFP from the
1st order neurons to the 2nd order neurons. Notably, the
TauGFP puncta in 2nd order neurons were positive for
Flotillin staining (Fig. 4e). Such TauGFP puncta in 2nd
order neurons may come from two sources: (1) TauGFP
exosomes internalized by the 1st order neurons; (2)
newly synthesized exosomes in the 1st order neurons
which contain TauGFP released by the internalized
exosomes. Thus, we sought to test whether TauGFP exo-
somes internalized by the 1st order neurons can be
directly transmitted to the 2nd order neurons (option 1).
To this end, we isolated exosomes from N2a cells
co-transfected with FlotillinGFP and RFP-Tau (TauRFP).
We utilized 3-chamber devices, as they allow the obser-
vation of the transmission of exosomes to an additional
population of neurons in the 3rd chamber. We reasoned
that if puncta in the 2nd or 3rd order neurons contain
both TauRFP and FlotillinGFP, they would represent the
exosomes internalized by the 1st order neurons, as it is
unlikely that the newly synthesized exosomes in the 1st
or 2nd order neurons encapsulate both TauRFP and
FlotillinGFP released by the internalized exosomes. As
shown in Fig. 4f, when the 1st order neurons were
treated with TauRFP and FlotillinGFP exosomes, majority of
puncta in the 2nd order neurons were positive for both
TauRFP and FlotillinGFP. In addition, puncta containing
TauRFP and FlotillinGFP were also observed in the 3rd order
neurons. These results suggest that exosomes can indeed
be directly transmitted between neurons.
Since recent studies have suggested that the spreading
of Tau occurs by a trans-synaptic mechanism [8, 9, 44],
we sought to determine whether and how the
(See figure on previous page.)
Fig. 4 The uptake and trans-synaptic transmission of Tau by cultured rat primary neurons via exosomes in microfluidic chambers. a Western blot
assay to analyze exosomes isolated from N2a cells transfected with TauGFP for 2 days. Note that only intact, no truncated TauGFP fusion protein
was detected, and that TauGFP occurred both in the neuronal and exosomal compartments. b Nanoparticle tracking analysis of isolated exosomes.
The distribution peaks around ~50 and ~80 nm, indicating the enrichment of exosomes in the preparations. c Cryo-electron tomography of isolated
exosomes. The left panel (overview) shows several exosomes (arrows) with an estimated size of ~50–100 nm. The isosurface representation in the right
panel shows two connected exosomes (the membranes are colored in blue and yellow respectively). d Uptake and transmission of TauGFP by neurons
cultured in microfluidic chambers with short microgrooves (150 μm). The 1st order neurons were treated with TauGFP exosomes (20 μg) at DIV25 for
24 h, when the 2nd order neurons were at DIV11. Neurons were stained with antibodies against MAP2 (red) and tubulin (blue). Arrows indicate TauGFP
positive vesicles. Note that TauGFP puncta were detected in the microgrooves (left panels) and also in the 2nd order neurons on the neuritic side (right
panels) that were not treated with TauGFP exosomes, indicating the uptake and the transmission of TauGFP via exosomes between the two populations
of neurons. Scale bar in Left panels = 20 μm; right panels = 10 μm. e Direct transmission of exosomes from 1st order neurons to the 2nd order neurons
in microfluidic chambers. Neurons were treated as described in d. Neurons were stained with antibodies against MAP2 (blue) and Flotillin (red). Scale
bar = 10 μm. Arrows indicate TauGFP exosomes. The colocalization of TauGFP with Flotillin indicates that Tau is indeed located in the exosomes. f Direct
transmission of exosomes from 1st order neurons to the 2nd and 3rd order neurons in microfluidic chambers. The 1st order neurons were
treated with TauRFP and FlotillinGFP positive exosomes (20 μg) at DIV24 for 24 h, when the 2nd and 3rd order neurons were at DIV17 and DIV10
respectively. Neurons were stained with antibodies against tubulin (blue). Majority of the puncta in 2nd (94.5 ± 3.7% of 220 puncta in 3 different
microfluidic chambers) and 3rd populations (85.7 ± 7.1% of 105 puncta in 3 different microfludic chambers) of neurons were positive for both
TauRFP and FlotillinGFP. Arrows indicate TauRFP and FlotillinGFP positive vesicles. Note that TauRFP and FlotillinGFP positive puncta were detected
in the 2nd and 3rd order neurons that were not treated with exosomes, indicating the uptake and the direct transmission of exosomes
between the three populations of neurons. Scale bar = 10 μm. g The transmission of TauGFP exosomes from axons of the 1st order neurons to
the 2nd neurons cultured in microfluidic chambers with long microgrooves (900 nm). The 1st order neurons were treated with TauGFP exosomes
(20 μg) at DIV25 for 24 h, when the 2nd order neurons were at DIV11. Neurons were stained with an antibody against tubulin (red). Scale bar = 10 μm.
Arrows indicate TauGFP positive exosomes. Note that TauGFP puncta were detected in the microgrooves (left panel) and also in the 2nd order neurons
on the neuritic side (right panels) that were not treated with exosomes. Since no dendrites project through the long microgrooves (900 μm) to the
neuritic side, the transmission of TauGFP exosomes occurs through axons of the 1st order neuron to the 2nd order neurons
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transmission of TauGFP exosomes can occur from the
axons of the 1st order neurons to the 2nd order neurons.
The microfluidic devices with short microgrooves
(~150 μm) used in the above experiments allow axons and
dendrites of the 1st order neurons to reach the neuritic side,
enabling the potential transfer of TauGFP exosomes to 2nd
order neurons. To distinguish between axons and dendrites,
we performed experiments in microfluidic devices with
long microgrooves (~900 μm) that prevent dendrites to
project to the neuritic side. TauGFP puncta were detected in
both microgrooves and 2nd order neurons (Fig. 4g), indicat-
ing that transmission of TauGFP can occur through axons.
Synaptic contacts are required for exosome-mediated
transmission of Tau
We next determined how the TauGFP exosomes were
transmitted from 1st order neurons to 2nd order neurons
in microfluidic devices. Two possible mechanisms may
explain the exosome-mediated transmission of Tau. (i)
Transmission takes place specifically through trans-
synaptic connections from 1st order to 2nd order neu-
rons. (ii) Exosomes in 1st order neurons are released into
the conditioned medium and then internalized by 2nd
order neurons at extrasynaptic sites (Fig. 5a). We ana-
lyzed the formation of synapses in 2nd order neurons
(DIV11) on the neuritic side by examining the co-
localization of the post-synaptic marker GluR1 (green)
and the pre-synaptic marker synaptophysin (red)
(Fig. 5b). Mature synapses were observed in 2nd order
neurons (DIV11) (Fig. 5, b3), although at a lower density
than in mature neurons (DIV 25 or DIV18) on the somal
side (Fig. 5, b1, b2, b5). Thus, synaptic contacts may
contribute to TauGFP transmission in this case. To
further determine the potential role of synaptic contacts
in the transmission of Tau, we examined whether the
transmission of TauGFP exosomes can occur when no
synapses are present in 2nd order neurons. To this end,
we selectively treated the 1st order neurons (DIV18)
when the 2nd order neurons were at a very early stage
(at DIV4). No synaptic contacts were detected in 2nd
order neurons at DIV4 (Fig. 5, b4). Notably, no TauGFP
puncta were detected in the cell bodies of the 2nd order
neurons at DIV4 (before synapse formation, Fig. 5c,
right panels), although TauGFP puncta in microgrooves
were detected (Fig. 5c, left panels). This indicates that
although TauGFP exosomes were taken up by the 1st
order neurons on the somal side, they were not trans-
mitted to 2nd order neurons. Taken together, these
results suggest that synaptic contacts are necessary for
the transmission of Tau by exosomes.
The low transmission of Tau into young neurons
(DIV4) could be explained either because these neurons
have not yet developed an uptake mechanism for
exosomes, or because the TauGFP exosomes were not
released on the neuritic side by the 1st order neurons.
To clarify these alternatives we examined the uptake of
exosomes by the young neurons (DIV4) and the release
of the TauGFP exosomes on the neuritic side by neurites
of 1st order neurons projecting through microgrooves
using flow cytometry. To analyze the uptake of exo-
somes, young neurons (DIV4) or old neurons (DIV11)
cultured in 24 well-plates were treated with purified
TauGFP exosomes and the conditioned medium was
collected for flow cytometry immediately after the
addition of exosomes (Exo_0h) or 24 h later (Exo_24 h).
After 24 h treatment, the amount of TauGFP exosomes in
the conditioned medium was strongly reduced for both
young neurons (DIV4) (down to 64.9 ± 12.7% of Exo_0h,
Fig. 5e) and old neurons (DIV11) (to 57.3 ± 9.8% of
Exo_0h, Fig. 5d), indicating that the uptake of TauGFP
exosomes occurs at similar rate in both young (DIV4)
and old (DIV11) neurons.
We further checked the uptake of TauGFP exosomes in
young neurons (DIV4) by immunofluorescence assay.
TauGFP exosomes were detected in neurons (arrows in
Fig. 5f ), indicating the internalization of exosomes. To
determine the release of TauGFP exosomes by the neur-
ites of the 1st order neurons on the neuritic side, condi-
tioned medium on the somal and neuritic sides of the
microfluidic chamber were collected for flow cytometry
immediately after (Exo_0h) or 24 h after the addition of
exosomes at the somal side (Exo_24 h). Nearly no
TauGFP exosomes were detected in conditioned medium
on the neuritic side after 24 h treatment of 1st order
neurons on the somal side with TauGFP exosomes
(Fig. 5g, h), regardless of the age of the 2nd order neu-
rons (DIV4 or DIV11). This result suggests that once
TauGFP exosomes were internalized by the 1st order
neurons, they were rarely released into conditioned
medium on the neuritic side by neurites of the 1st order
neurons. Thus the transmission of TauGFP from the 1st
order neurons to the 2nd order neurons (DIV11) occurs
through synaptic contacts: TauGFP exosomes are released
by presynapses and taken up by postsynapses.
To highlight the importance of synaptic connections
for the transmission of Tau by exosomes, we performed
another set of experiments using 3-chamber devices.
When neurons were plated in all the three chambers,
treatment of the neurons in the 1st chamber with TauGFP
exosomes resulted in the distribution of TauGFP puncta
in ~20% (20% ± 12.9%) of 2nd order neurons and ~4%
(4.5 ± 0.5%) of 3rd order neurons. This suggests that
TauGFP was transmitted (Fig. 5 i, j). However, when neu-
rons were plated in the 1st and 3rd chambers, but not
2nd chambers (Additional file 4: Figure S4, A) (so that
the axons from the two populations of neurons pro-
jected to the 2nd chamber), no synapses were formed
between them. Treatment of the neurons in the 1st











Fig. 5 (See legend on next page.)
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chamber with TauGFP exosomes resulted in the distribu-
tion of TauGFP puncta in microgrooves between 1st
chamber and 2nd chamber (Additional file 4: Figure S4, B),
indicating the uptake of TauGFP exosomes by neurons in
the 1st chamber. However, no TauGFP exosomes were de-
tected in microgrooves between the 2nd and 3rd chamber
and in neurons in the 3rd chamber. This means that no
transmission of TauGFP occurred between the two popula-
tions of neurons (Additional file 4: Figure S4, B). The re-
sults confirm that synaptic contacts are necessary for the
transmission of Tau by exosomes.
Collectively, these data argue that exosomes can medi-
ate the trans-synaptic transmission of Tau. Notably,
when the 1st order neurons were treated with exosomes
that were disrupted by sonication, no TauGFP puncta
were detected in the microgrooves and the 2nd order
neurons (data not shown), indicating that the integrity
of exosomes is necessary for the transmission of Tau
protein.
To exclude the possibility that the transmission of exo-
somal Tau between neurons is only applied to exosomes
derived from N2a cells, we treated neurons in microfluidic
devices with exosomes derived from neurons infected with
adeno-virus expressing CFP-Tau40 (TauCFP). Similar to
treatment with N2a cell-derived exosomes, CFP puncta
were observed in the 2nd order neurons (Additional file 5:
Figure S5B, right panels), suggesting exosomes can indeed
serve as a carrier to regulate the transfer of Tau between
neurons independently of the origin of exosomes.
We also tested the uptake of TauGFP exosomes in
organotypic hippocampal slice cultures. As shown in
Fig. 6a, we observed co-localization of TauGFP with the
neuronal marker MAP2 (a1) and microglial marker Iba1
(a2, a3) but not with the astrocytic marker GFAP (a4),
indicating TauGFP exosomes were preferentially internal-
ized by neurons and microglia. Microglia are more com-
petent in uptake of exosomes than neurons, as higher
percentage of microglia (24.8 ± 14.1%) than neurons
contained TauGFP exosomes (Fig. 6b). When the exo-
somes were disrupted by sonication, no uptake of TauGFP
was observed (Additional file 6: Figure S6), consistent with
the observation in primary neurons, indicating that
exosomes need to be intact for internalization to occur.
The release of aggregation-prone Tau via exosomes by
an N2a cell model of Tau aggregation
Several recent studies showed that pre-formed Tau
aggregates can be taken up by cultured cells and subse-
quently induce local accumulation of other Tau molecules
[14, 15]. We asked whether Tau aggregates can be
(See figure on previous page.)
Fig. 5 Synaptic contacts are required for exosome-mediated transmission of TauGFP. a Diagram illustrating the possible mechanisms underlying
exosome-mediated Tau transmission. (i) Transmission occurs specifically through trans-synaptic connections from 1st order to 2nd order neurons.
(ii) Exosomes in 1st order neurons are released into the conditioned medium and then internalized by 2nd order neurons. b Formation of synaptic
contacts at different states of maturation. (b1, b2) Neurons were stained for post-synaptic marker GluR1 (green) and pre-synaptic marker synaptophysin
(SynPh) (red). The co-localization of GluR1 and synaptophysin indicates formation of synaptic contacts (white arrows on right panel). Synaptic
connections were formed in the 1st order mature neurons (DIV 25 or DIV18) on the somal side (b1, b2) and also in the 2nd order old neurons
on the neuritic side (DIV11) (b3), but not in the 2nd order young neurons (DIV4) (b4). Scale bar = 10 μm. (b5) Quantification of synapse density
shown in b1-b4. Synapses are formed in neurons at DIV11, although the density is lower than that in mature neurons (DIV18 and 25). Notably,
nearly no synapses are formed in young neurons at DIV4. Error bars: SEM; n = 3 in b5. Student t-test: **p < 0.01. c No transmission of TauGFP exosomes
from mature neurons (DIV18) to very young neurons (DIV4) cultured in microfluidic chambers. The 1st order neurons were treated with TauGFP
exosomes (20 μg) at DIV18 for 24 h, when the 2nd order neurons were at DIV4. Neurons were stained with an antibody against tubulin (red).
Scale bar in left panel = 20 μm; in right panel = 10 μm. Arrows indicate TauGFP positive exosomes in the microgrooves (left side, middle), but
not in the 2nd order neurons on the neuritic side (right side, bottom) that were not treated with exosomes, indicating no transmission of
TauGFP via exosomes between the two populations of neurons. d, e FACS analysis of the uptake of TauGFP exosomes by young (DIV4) and old
neurons (DIV11). Neurons were treated with TauGFP exosomes (20 μg) for 24 h. Conditioned medium was collected immediately after the
addition of TauGFP exosomes (Exo-0 h) or 24 h later (Exo-24 h) for flow cytometry. The left and middle panels show a representative readout of
the flow cytometry. Right panel: quantification of 3 experiments. Note that TauGFP exosomes in conditioned medium is dramatically reduced
after 24 h treatment, indicating the uptake of these exosomes by young and old neurons (DIV4 or DIV11). Error bars: SD; n = 4 and n = 3 in d and e
respectively. Student t-test: *p < 0.05. f The internalization of TauGFP exosomes by young neurons (DIV4). Young neurons (DIV4) were treated with
TauGFP exosomes (20 μg) for 24 h and then stained with an antibody against tubulin (red). Scale bar = 10 μm. Arrows indicate TauGFP positive
exosomes. Note that TauGFP puncta are detected inside neurons, suggesting the uptake of TauGFP exosomes by young neurons. g, h FACS analysis
showing that there is no release of TauGFP exosomes into conditioned medium on the neuritic side. The 1st order neurons cultured on the somal side
in microfluidic chambers were treated with TauGFP exosomes (20 μg) for 24 h. Conditioned medium on the somal side or neuritic side was collected
immediately after the addition of TauGFP exosomes (Exo-0 h) or 24 h later (Exo-24 h) for flow cytometry. The left 3 panels show a representative
readout. The right panels: quantification of 3 experiments. Almost no TauGFP positive exosomes were detected in the conditioned medium on the
neuritic side, indicating that the internalized TauGFP exosomes were not released into the conditioned medium on the neuritic side by the 1st order
neurons. Error bars: SD, n = 3. Student t-test: ** p < 0.01. i Transmission of TauGFP exosomes from 1st order neurons to the 2nd and 3rd order neurons in
triple-chamber devices. The 1st order neurons cultured in the 1st chamber were treated with TauGFP exosomes (20 μg) at DIV24 for 24 h. Neurons were
stained with an antibody against tubulin (red). Arrows indicate TauGFP exosomes. Note the presence of TauGFP exosomes in all the three population of
neurons indicating transmission of TauGFP via exosomes between the three different populations of neurons. Scale bars = 10 μm. j Quantification of
the percentage of neurons in all the three channels with TauGFP exosomes. Error bars: SEM; n = 3. Student t-test: * p < 0.05, **p < 0.01
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encapsulated into exosomes and subsequently mediate the
propagation of Tau aggregation. To this end, we made use
of a cell model overexpressing the pro-aggregant 4-repeat
domain of Tau with the mutation ΔK280 (TauRDΔK), since
Tau forms aggregates in this cell model [30, 38].
We isolated exosomes from conditioned medium of this
cell model and separated the soluble Tau and Tau aggre-
gates using sarkosyl extraction. The sarkosyl extracts were
used as controls. Consistent with our previous studies [38,
45], the sarkosyl-insoluble pellet from the cell lysates
contained not only the protein TauRDΔK but also two
smaller fragments (F2 and F3) which are generated by
endoproteases and are required for nucleated aggregation
(Fig. 7a). By contrast, the exosomal lysates contained only
TauRDΔK, but fragments F2 or F3 are below detectability
(Fig. 7a). In cell lysates, only ~3% of Tau was insoluble,
while in exosomal extracts insoluble Tau was increased to
~12% (Fig. 7b). This result indicates that insoluble Tau is
enriched in exosomes compared to cell lysates.
Since high speed centrifugation was used to isolate
exosomes from the conditioned medium of N2a
cells, this raises the question whether Tau aggregates
detected in exosomal preparations actually represent the






Fig. 6 Uptake of TauGFP exosomes by neurons and microglia in cultured organotypic hippocampal slices. a Immunofluorescence assay showing
the uptake of TauGFP exosomes by hippocampal slice cultures. Hippocampal slice cultures were incubated for 24 h with exosomes (20 μg)
isolated from N2a cells expressing TauGFP. Cultures were afterwards stained for neuronal marker MAP2 (red, a1), microglial marker Iba1 (red, a2, a3)
or astrocytic marker GFAP (red, a4). TauGFP colocalizes with MAP2 (A1) and Iba1 (a2, a3) suggesting the uptake of exosomes by neurons (a1) and
microglia (a2, a3). Nearly no colocalization of TauGFP with GFAP is observed (a4), indicating no internalization of exosomes by astrocytes. Scale
bars = 10 μm. b Quantification of the uptake of TauGFP exosomes by neurons, microglia and astrocytes shown in (a). Significantly higher
percentage of microglia (24.8 ± 14.1%) than neurons (12.3 ± 11.2%) exhibits uptake of exosomes (n = 22–24 slices). Nearly no uptake of exosomes
is observed in astrocytes. Error bars: SEM. ANOVA: *** p < 0.001







Fig. 7 (See legend on next page.)
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dead cells. To clarify this issue, we performed sucrose
gradient centrifugation to fractionate the exosomal prepara-
tions and the sarkosyl insoluble pellet of the cell lysates,
resp. and then examined whether Tau aggregates exhibit
the same density as exosomes. For exosomal preparations,
both exosomal marker Alix and Tau were only detected in
fraction 4 with a density of ~1.19 g/ml (Fig. 7c). This is
consistent with exosomal density (1.08 to 1.22 g/ml),
indicating our preparations were enriched in exosomes. For
the sarkosyl insoluble pellet of cell lysates, Tau was mainly
found in fractions 1 and 9 (Fig. 7d, lower panel, lane 1, 9).
The Tau in fraction 9 may be the soluble species that
resulted from Tau aggregates, owing to the equilibrium
between soluble and insoluble Tau. No Tau was detected in
the exosomes-enriched fraction 4 (Fig. 7d, lower panel, lane
4). Of note, Alix was detected in fraction 4 (Fig. 7d, upper
panel, lane 4), which might derive from intracellular
vesicles contaminating the pellet of sarkosyl extraction.
Collectively, these data indicate that the presence of
TauRDΔK in exosomes is not due to the contamination of
Tau aggregates in the exosomal preparation.
We further characterized isolated exosomes from
N2a cells with nanoparticle tracking analysis, which
showed that they mainly contained vesicles with a
diameter of around 100 nm (typical for exosomes)
(Fig. 7e). This was confirmed by AFM, which showed
that the size of most of the vesicles was 40–100 nm
(Fig. 7f ). Finally, the isolated exosomes were analyzed
with cryo-EM. The vesicles exhibited a spheroidal
shape with a diameter of ~100 nm (Fig. 7g), which was
consistent with exosomal morphology. Interestingly,
materials of high density (indicated in blue, Fig. 7g,
right lower panel) were detected in the vesicles.
However, whether they represent Tau aggregates is
not certain.
Exosomes derived from N2a cells expressing
aggregation-prone TauRDΔK induce aggregation of
full-length Tau in N2a cells
Given that exosomes derived from N2a cells expressing
TauRDΔK contain insoluble Tau, we asked whether such
exosomes could induce the aggregation of full-length
Tau molecules in N2a cells. We previously reported that
overexpressing aggregation-prone Tau fragments (e.g.
fragment F3 = Tau258–360) can induce the aggregation of
full-length Tau with the ΔK280 mutation (TauΔK280)
[38, 45]. By analogy, we tested whether exosomes de-
rived from N2a cells expressing TauRDΔK can induce
the aggregation of hTauΔK. We monitored Tau aggre-
gates using thioflavine S staining. The treatment by
such exosomes indeed induced aggregation in N2a cells
expressing TauΔK (~20-30/3-4X104 cells) (Fig. 7h, lower
panel). Of note, treatment with sonicated exosomes
failed to induce Tau aggregation (Fig. 7h, upper panel).
These results demonstrate that exosomes can mediate
the propagation of Tau aggregation.
Exosomes in CSF from AD patients and control subjects
contain Tau and can induce Tau aggregation in cultured
N2a cells
Given that Tau can be released by primary neurons via
exosomes, we further searched for in vivo evidence of
exosomal Tau. To this end, we isolated exosomes from
the CSF of AD patients or control subjects (Table 1) and
examined whether Tau was a component of such exo-
somes. The purification of exosomes by this method was
validated with sucrose gradient centrifugation, revealing
the presence of the exosomal marker protein Flotillin at
a density of 1.16–1.24 g/ml [23] and electron micros-
copy [34]. We first characterized the isolated exosomes
using nanoparticle tracking. The size distributions of
(See figure on previous page.)
Fig. 7 Tau aggregates are preferentially released via exosomes by a cell model of tauopathy, which can induce aggregation of Tau in N2a cells.
Tet-inducible N2a cells were induced to express TauRDΔK for 2 days by addition of doxycyclin. Then the cells were harvested for sarkosyl extraction
to separate soluble Tau and insoluble Tau. The conditioned medium was collected for isolation of exosomes. S and P denote supernatant and pellet
of sarkosyl extraction respectively. a TauRDΔK aggregates in N2a cells and in exosomes. Soluble Tau and Tau aggregates in N2a cells expressing TauRDΔK
or exosomes from this cell model were separated by sarkosyl extraction. The protein loading ratio between supernatant and pellet for N2a cells was
1:60, for exosomes was 1:9. Note that fragment F2 and F3 were detected in pellet of cell extracts but not in pellet of exosomal extracts.
b Quantification of TauRDΔK shown in (a). Note that much more TauRDΔK aggregates were detected in exosomes than in N2a cells. Error
bars: SD; n = 3. Student t-test: ** p < 0.01. c Analysis of isolated exosomes separated by sucrose gradient centrifugation. TauRDΔK appears in
fraction 4, coincident with the exosomal marker Alix. d Analysis of sarkosyl pellet of cell lysates separated by sucrose gradient centrifugation. TauRDΔK
is enriched in fraction 1 and 9, but not in fraction 4– the fraction shown to contain exosomes in (c). This indicates that the presence of TauRDΔK in
exosomes is not due to the contamination of Tau aggregates. e Nanotracking analysis of isolated exosomes. The size distribution peaks at ~100 nm,
which is typical for exosomes. f Atomic force microscopy of isolated exosomes. The diameters of the majority of the vesicles are 40–100 nm. The
average diameter of the exosomes isolated from N2a cells expressing TauRDΔK is 67.2 ± 15.3 nm and the average height is 2.2 ± 0.8 nm. The exosomes
appear to be disk-like shaped. g Cryo-electron tomography of isolated exosomes (compare Fig. 1g). h Induction of aggregation of full-length TauΔK in
N2a cells by exosomes from N2a cells expressing TauRDΔK. N2a cells were transfected with pro-aggregant TauΔK and induced to express the protein for
1 day. Then the cells were treated with exosomes (20 μg) derived from N2a cells expressing TauRDΔK and continuously induced to express TauΔK for
additional 2 days. TauΔK was labeled with K9JA antibody (red). Thioflavine S staining was performed to monitor Tau aggregates (green, arrow). Hoechst
staining was used to label nuclei (blue). Note that ThS positive cells were detected in N2a cells (~20-30/3-4X104 cells, repeated 3 times) treated with
exosomes containing TauRDΔK, but not in N2a cells treated with broken exosomes. Arrow indicates Tau aggregates. Scale bars = 10 μm
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the particles showed maxima around 70–100 nm
(Additional file 7: Figure S7), indicating that the prep-
arations were indeed enriched in exosomes.
Western blot analysis with pan-Tau antibody K9JA
revealed multiple bands between 53kD and 80kD in both
AD and control exosomal preparations (Fig. 8, a1). A
further band of ~180kD (arrowhead in Fig. 8, a1-a3) was
detected in both AD and control exosomal preparations,
indicating the presence of SDS-stable Tau oligomers in
exosomes. To determine whether the Tau oligomers
were selectively encapsulated into exosomes, we checked
Tau in CSF before exosome isolation. Two Tau bands
above 50kD and 60kD were detected, but no band around
180kD (Fig. 8b), suggesting that the Tau oligomers were
enriched in exosomes, compared to the free CSF Tau. No
significant differences in the levels of Tau was observed
between exosomes from AD and from controls (Fig. 8,
c1). Further analysis of Tau phosphorylation revealed that
the ~180kD band (arrowhead in Fig. 8, c2, c3) and two
other Tau bands (~53kD and ~68kD, arrows) were
phosphorylated at the 12E8 and PHF1 sites (Fig. 8, c2, c3).
This is in contrast to Tau in exosomes from cultured
neurons which is hypophosphorylated based on the
increased mobility during gel electrophoreses (Fig. 1c). No
significant differences in the levels of Tau phosphorylated
at 12E8 and PHF1 sites was detected between exosomes
from AD and from controls (Fig. 8, c2, c3). Notably,
multiple Tau bands between 53kD and 68kD (Fig. 8, a1,
indicated by *) were not recognized by 12E8 and PHF1
antibodies (Fig. 8, a2, a3).
Taken together, these data suggest that both monomeric
and oligomeric Tau phosphorylated at 12E8 and PHF1
sites as well as monomeric Tau unphosphorylated at 12E8
and PHF1 sites can be secreted via exosomes in vivo in
human brains, and in both cases the Tau monomers or
oligomers are encapsulated within the exosomes.
Recently, it was shown that exosomes from patients with
Parkinson Disease (PD) and Dementia with Lewy Bodies
(DLB) can induce α-synuclein aggregation [34]. This
prompted us to examine whether exosomes isolated from
human CSF are able to seed Tau aggregation, since we
showed above that these exosomes contain Tau oligomers
(Fig. 8a), and that exosomes isolated from N2a cells ex-
pressing TauRDΔK can induce Tau aggregation (Fig. 7h).
We took advantage of a split-luciferase fragment comple-
mentation technique to analyze whether exosomes from
human CSF can promote TauRDΔK aggregation (Fig. 8d).
Treatment with exosomes from AD or control CSF
(Table 2) dramatically increased TauRDΔK aggregation, as
they elevated the luminescence signal by ~50 and 40%
respectively compared to control treated with PBS (Fig. 8e).
Slightly higher aggregation was induced by exosomes from
AD than exosomes from controls, but this did not reach
statistical significance (Fig. 8e).
Discussion
Tau pathology spreads in a hierarchical pattern in AD. It
has been proposed that this can occur through the direct
transfer of Tau between neurons through neuronal syn-
aptic connections [8, 9], but the mechanism underlying
this process remains elusive. Here, we demonstrate that
exosomes can act as carriers to mediate the direct trans-
synaptic transmission of Tau.
In cultured primary neurons, the secretion of Tau has
been proposed to partly depend on pre-synaptic vesicle
secretion [11], however, Tau is not found in the synaptic
vesicle proteome [46]. Other mechanisms thus must be
involved in the secretion of Tau. Growing evidence
suggests that Tau is released via an unconventional
secretory pathway independent of the ER/Golgi medi-
ated secretory pathway [12]. This pathway includes 4
modes: direct translocation from the cytoplasm across
the plasma membrane, release via secretory lysosomes,
microvesicle shedding, or exosome release [47]. It has
been a matter of debate whether Tau is a component of
exosomes, as some studies showed Tau to be present in
exosomes from different cells including neurons [26, 48],
whereas others did not find this [11, 12, 49]. Here, we
show that Tau is indeed released via exosomes by
cultured neurons, by N2a cells overexpressing human
Tau and in vivo in human brain. The secretion of exoso-
mal Tau by neurons is not an artifact due to the associ-
ation with the exosomal surface by Tau protein from
dead cells, because we find that Tau is located inside
exosomes (Fig. 3). In addition, chemical stimulation of
neurons increases secretion of exosomes containing Tau
without obvious neurotoxicity (Fig. 2). This further
argues that exosomal Tau release is a physiological
process regulated by neuronal activity. The failure of
some earlier studies to detect exosomal Tau may be ex-
plained as follows: (1) Only a small amount of exosomes
isolated from limited starting material was used to detect
Tau. Since Tau is not a major component of exosomes
(Fig. 1a), and since only a small fraction of released Tau
(~2%) is associated with exosomes (Fig. 1b), a robust
amount of exosomes is necessary for the analysis of
associated Tau. (2) Some cell types could encapsulate
Tau into exosomes only poorly, as both biosynthesis of
exosomes and their contents may vary between cells
[32]. It is worth noting that although we detect Tau in
exosomes from mature neurons (DIV14-21), we found
no Tau in exosomes from immature neurons (DIV9),
consistent with another study [29]. Thus, the Tau
content of neuronal exosomes appears to be develop-
mentally regulated and cell-type dependent.
We found that the Tau physiologically released via exo-
somes by cultured neurons was both intact and hypopho-
sphorylated, compared with cytosolic Tau. It is not clear
whether exosomes accumulate preferentially Tau in a low








Fig. 8 (See legend on next page.)
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state of phosphorylation, or whether the ingested Tau is
dephosphorylated by some exosomal phosphatase. It is
worth noting that hypophosphorylated intact Tau was
detected in conditioned medium of neuronal cultures in a
previous study [11], although such extracellular Tau was
demonstrated to be non-exosome associated, as Tau is
barely detected in exosomal preparations, probably due to
the limited material loaded. By contrast, another report
stated that only C-terminally truncated Tau lacking the
microtubule binding domain is released by cultured neu-
rons or other types of cells [50] and a small fraction of
extracellular Tau (<0.2%) is indeed present in exosomes.
The cause of the discrepancy (truncated Tau v.s. intact Tau)
between these papers is unknown. In addition, there has
been a debate whether human CSF contains intact Tau or
truncated Tau, but independently of that we observed intact
Tau in CSF from AD and control subjects and also in exo-
somes derived from such CSF (Fig. 8a, c).
Pathological proteins or miRNAs in exosomes have
emerged as potential biomarkers for AD and other neurode-
generative diseases [34, 51, 52]. A recent study demonstrated
the presence of Tau in exosomes isolated from blood of pa-
tients with AD or frontotemporal dementia (FTD) and that
the exosomal levels of total Tau and Tau phosphorylated at
T181 or S396 for AD and FTD were significantly higher than
in control subjects [51]. We show here that Tau is present in
exosomes from human CSF as well. However, distinct from
blood-derived exosomes, there is no significant difference in
the levels of Tau phosphorylated at 12E8 (pS262 + pS356) or
PHF1 sites (pS396 + pS404) between CSF-derived exosomes
from AD and control cases. In addition, the presence of Tau
phosphorylated at 12E8 and PHF1 sites in CSF-derived
exosomes is in contrast to the absence of such tau species in
exosomes derived from cultured neurons.
Since Tau oligomers are considered the major toxic spe-
cies in AD, it is of interest to know whether they occur in
exosomes as well. We find that SDS-stable Tau oligomers
were preferentially encapsulated into CSF-derived exo-
somes from AD and control cases (Fig. 8a). Consistent
with our results, Saman et al. reported the identification
of Tau oligomers in exosomes isolated from CSF of AD,
but whether Tau oligomers are also present in exosomes
from control subjects was not determined in that study
[28]. They found that the AD CSF-derived exosomes con-
tained 35-40kD truncated Tau species and Tau trimers of
~105kD [28]. This is different from what we identified
here: the exosomal Tau from both AD and control CSFs
consisted mainly of species of 55-68kD that likely repre-
sent intact Tau isoforms and Tau oligomers of ~180kD
that might be trimers of intact Tau (Fig. 8a, c). The cause
of the discrepancy between these two studies is unclear,
but it may be related to the different preparations of CSF,
as Saman et al. used postmortem CSF while we used
freshly collected CSF. As Tau oligomers may be neuro-
toxic, the exosome-mediated release of Tau oligomers
may actually be a protective process for neurons to clear
these toxins, by analogy to the observation of exosome-
mediated release of alpha-synuclein [53]. However, on the
other hand, we showed that such exosomes from human
CSF promote tau aggregation (Fig. 8e), probably because
the exosomal Tau oligomers can seed the aggregation of
other Tau molecules, and thereby mediate the propagation
of tau pathology.
Some recent studies proposed that Tau pathology can
spread via a trans-synaptic pattern [8, 9, 44]. However, direct
evidence showing transmission of Tau from presynaptic to
postsynaptic compartments is still lacking. Microfluidic
devices are excellent tools to study the transitions of Tau be-
tween cell compartments and across cells. By using these
chambers, we found that Tau is transmitted between neu-
rons via exosomes (Fig. 4). Importantly, we showed that part
of the exosomes may be taken up as intact vesicles by the 1st
order neurons and then released and internalized by the 2nd
order neurons. Our results indicate that the uptake of exo-
somes does not necessarily mean the fusion of exosomes
with the plasma membrane to allow the direct transfer of
exosomal content to the cytosol. Consistent with our results
it has been shown that exosomes are recruited as single vesi-
cles to the cell cytosol, instead of fusing with plasma mem-
brane, and after internalization, the majority of the
internalized exosomes move toward lysosomal compart-
ments [54]. In addition, our results suggest that some
(See figure on previous page.)
Fig. 8 Exosomes isolated from CSF of AD or control subjects contain Tau and induce TauRDΔK aggregation. a The presence of Tau monomers and trimers in
exosomes determined with western blots. Besides Tau monomers, Tau trimers (indicated by arrowheads, top right) ran around 180kD were detected in both
exosomes from AD and controls. These Tau trimers were phosphorylated at 12E8 sites (a2) and PHF1 (a3). Two Tau monomer bands were also phosphorylated
at PHF1 sites and 12E8 sites (indicated with arrows). Between the phosphorylated Tau monomer bands, other Tau bands were not phosphorylated at PHF1
and 12E8 sites (a1, indicated by *). b Tau in CSF before isolation of exosomes. Monomeric Tau (doublet between Mr 55-70kD (indicated by arrows), but no Tau
oligomers of ~180kD was detected. c Quantification of Tau shown in a. No significant differences of the amount of total Tau (c1) and Tau phosphorylated at
12E8 sites (c2) and PHF1 sites (c3) were observed between exosomes isolated from AD and controls. Error bars: SD. Student t-test: n.s., not significant. d Diagram
showing the luciferase protein-fragment complementation assay. N2a cells were co-transfected with TauRDΔK fused to split luciferase constructs (N:
N-terminal part of luciferase, C: C-terminal part of luciferase). A luminescence signal is only detected after complementation of both split
luciferase fragments (e.g. during dimerization and oligomerization of TauRDΔK) and indicates the induction of TauRDΔK aggregation. e Promotion
of TauRDΔK aggregation by exosomes from human CSF. Luminescence increases in reporter cells upon treatment with exosomes prepared from equal
volumes of CSF from AD (n= 13) or controls (n= 13). All measurements were performed in triplicates. **, p < 0.001, n.s., non-significant, one way ANOVA
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internalized exosomes may be spared from this pathway, and
can be released and taken up by other neurons.
Moreover, we showed that the exosome-mediated trans-
mission of TauGFP requires synaptic connections between
the 1st order neurons on the somal side and 2nd order
neurons on the neuritic side. This view is based on three ob-
servations. (1) No exosomes were detected in conditioned
medium on the neuritic side, indicating that the transition of
TauGFP does not occur because exosomes of 1st order
neurons are released into the conditioned medium and then
internalized by 2nd order neurons at extrasynaptic sites
(Fig. 5a, ii). (2) There is no transmission of TauGFP exosomes
from the 1st order to the young 2nd order neurons (DIV4) on
the neuritic side (which lack synaptic connections) (Fig. 5c),
indicating that synaptic contacts are necessary for exosome-
mediated Tau transmission. (3) In the 3-chamber micro-
fluidic devices, transmission of TauGFP was observed from
neurons in the 1st chamber to neurons in the 2nd and 3rd
chamber (Fig. 5i). However, no transmission of TauGFP was
observed from neurons in the 1st chamber to neurons in the
3rd chamber, when no neurons were seeded in the 2nd cham-
ber (Additional file 4: Figure S4). In this case, the two popu-
lations of neurons do not form synaptic connections, which
confirms that synaptic connections are necessary for the
transmission of TauGFP. Our results argue that the trans-
synaptic transmission of TauGFP occurs because exosomes
are preferentially released at presynapses of the 1st order
neurons and subsequently taken up by the postsynapses of
the 2nd order neurons (Fig. 9). However, it should be pointed
out that here it is the internalized exosomes added to the
somal side that are preferentially released at pre-synaptic
terminals on the neuritic side. By contrast, the fusion of
multivesicular bodies with membranes in cell bodies and
dendrites may result in the release of “endogenous” exo-
somes at these sites as well [39].
Our study showed that Tau aggregates are preferen-
tially released via exosomes by an N2a cell model of Tau
aggregation, as higher percentage of Tau is insoluble in
exosomes than in N2a cells (Fig. 7a, b). In addition, we
found that Tau oligomers are present in human CSF-
derived exosomes (Fig. 8a). Importantly, we showed that
the Tau-aggregates containing exosomes can induce Tau
aggregation in cultured cells (Figs. 7h and 8e). Taken
together, our study implies that exosomes could play a
role in the spreading of Tau pathology. Notably,
exosome-associated Tau aggregates appear to be more
efficient in seeding Tau aggregation than the free Tau
aggregates, since the broken exosomes failed to induce
Tau aggregation. Thus, although exosomal Tau only ac-
counts for a tiny portion of extracellular Tau, the contri-
bution of exosomes in the spreading of Tau pathology
may not be negligible. Indeed, this view is supported by
a recent study showing that inhibition of exosome
synthesis halts tau propagation in a mouse model [55].
In fact, the preferential release of internalized exosomes
at pre-synaptic terminals would naturally explain why
Tau pathology spreads in a hierarchical pattern rather
than in a proximity-dependent pattern. The scenario
includes several steps: (1) Tau aggregates containing
exosomes are released in one brain area and internalized
by neighbouring neurons; (2) Internalized exosomes
undergo axonal transport and finally are released only
at pre-synaptic terminals. (3) The released exosomes
are taken up by the synaptically connected neurons in
another area and subsequently induce Tau aggregation
in these neurons. Recent studies proposed that certain
Tau aggregates can undergo direct trans-synaptic
transmission [56, 57]. However, it is not clear whether
such Tau aggregates can only be released at pre-
synaptic terminals. If such Tau aggregates could be
released along the axon shaft, one would expect the
occurrence of the proximity-dependent spreading of
Tau pathology, unless other mechanisms exist that
prevent the uptake of such Tau aggregates by sur-
rounding neurons.
Recently, passive immunotherapies with Tau specific
antibodies have been reported to retard the progress
of Tau pathology in Tau transgenic mice. It has been
proposed that Tau antibodies might achieve thera-
peutic effects by capturing extracellular Tau seeds and
thereby prevent the seeding and trans-cellular propa-
gation of Tau pathology [58–60]. However, given that
exosomes shielding the contained Tau aggregates from
recognition by antibodies may mediate the propaga-
tion of Tau aggregation, there is the question whether
antibodies targeting only extracellular Tau can indeed
terminate the progression of Tau pathology.
Fig. 9 Diagram of exosome-mediated Tau transmission. (1) When
Tau-containing exosomes are released into extracellular space, they
can be taken up by neurons. (2) The internalized exosomes undergo
axonal transport and finally are released at pre-synaptic terminals. (3)
The released exosomes are taken up by the synaptically connected
neurons, resulting in the distribution of Tau in these recipient cells
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Finally, we found that exosomes are internalized by
neurons and microglia but not by astrocytes in cultured
organotypic hippocampal slices. Microglia are more ef-
ficient than neurons in uptake of exosomes. To date,
whether or not extracellular vesicles including exo-
somes uptake is a cell type-specific process remains a
matter of debate [61]. A previous report showed that
oligodendrocytes-derived exosomes are predominantly
internalized by microglia via micropinocytosis, but not
by neurons and astrocytes [62]. The inconsistence be-
tween this study and our study may be related to the
different origins of exosomes (N2a cells v.s. oligoden-
drocytes). The significance of the preferential internal-
ization of exosomes by microglia over neurons requires
further investigation.
Conclusion
Our data demonstrate that different Tau species including
monomers, oligomers and aggregates may be released via
exosomes by neurons or cultured cells. The Tau aggregates-
containing exosomes derived from human CSF or cultured
cells can promote Tau aggregation. Release of exosomes is
enhanced by neuronal activity. Exosomes are involved in
the trans-synaptic transmission of Tau between neurons
and thus may contribute to the spreading of Tau pathology.
Additional files
Additional file 1: Figure S1. Tau in exosomes from cortical neurons is
not phosphorylated at PHF1 and AT8 sites. Tau in neuronal lysates is
phosphorylated at PHF1 and AT8 sites (lanes 1, 4), whereas Tau in
dephosphorylated neuronal lysates and exosomal Tau are not detectably
phosphorylated at these sites (lane 2, 3 and 5, 6). (PNG 30 kb)
Additional file 2: Figure S2. Atomic force microscopy of exosomes
from cortical neurons. (A) The amplitude, height and 3D images of AFM.
Scale bar = 100 nm. (B) Quantification of the size of exosomes. The
majority of the vesicles are 40–100 nm. (PNG 89 kb)
Additional file 3: Figure S3. Projections of neurons cultured in
microfluidic devices with short microgrooves (150 μm). The 1st order
hippocampal neurons were seeded on the somal side (left) of the
microfluidic chamber. Fourteen days later, the 2nd order hippocampal
neurons were seeded on the neuritic side (right) and cultured for
additional 10–11 days. Neurons were treated on the neuritic side (A) or
somal side (C) with DiI for 2 to 3 h. The living cells were then imaged
using fluorescence microscopy. Scale bar = 10 μm. When the 2nd order
neurons on the neuritic side were treated with DiI (A, top right panel),
cell bodies of the 1st order neurons whose neurites projected through
microgrooves to the neuritic side were positive for DiI staining
(arrowhead in A, top left panel), by contrast, cell bodies of neurons that
do not project to the neuritic side were not positive for DiI staining
(arrows in A, bottom left panel). When the 1st order neurons on the
somal side were treated with DiI (C, top left panel), their processes that
projected through microgrooves to the neuritic side were stained by DiI
(C, top right panel). However, no cell bodies of the 2nd order neurons
(arrows in C, bottom right) were positive for DiI staining, indicating that
the 2nd order neurons do not project through microgrooves to the somal
side. The result of A and C is illustrated by B and D resp.. The flow of the
conditioned medium (indicated by arrow) prevents the diffusion of
added Dil from treated side to the opposite side. (PNG 175 kb)
Additional file 4: Figure S4. No transmission of TauGFP exosomes from
1st order neurons in the first chamber to the 2nd order neurons in the
third chamber. (A) Diagram to show the culture of neurons in 3-chamber
microfluidic devices. Neurons were seeded in the 1st and 3rd chambers at
the same time, but not in the 2nd chamber. (B) No transmission of
TauGFP exosomes from neurons (DIV10) cultured in 1st chamber to
neurons cultured in 3rd chamber. The 1st order neurons cultured in
the 1st chamber were treated with TauGFP exosomes (20 μg) at DIV10
for 24 h. Neurons were stained with an antibody against tubulin (red).
Arrows indicate TauGFP positive exosomes in the first channel and in the
axons projecting from the 1st order neurons. Note the absence of TauGFP
positive exosomes in the third channel indicating no transmission of TauGFP
via exosomes between the two populations of neurons. Scale bar = 10 μm.
(PNG 118 kb)
Additional file 5: Figure S5. Uptake and transmission of TauCFP by
neurons cultured in microfluidic chambers via exosomes derived from
cultured neurons. (A) Nanoparticle tracking analysis of exosomes derived
from primary neurons transfected with TauCFP. The size distribution peaks
at ~90 nm, indicating the enrichment of exosomes in the preparations.
(B) Uptake and transmission of exosomes containing TauCFP isolated as in
(A) by neurons cultured in microfluidic chambers with long microgrooves
(900 nm). The 1st order neurons at DIV25 were treated for 24 h with
exosomes (20 μg) isolated from primary cortical neurons infected with
adeno-virus expressing TauCFP, when the 2nd order neurons were at DIV11.
Neurons were then fixed and stained for immunofluorescence microscopy
with antibodies against MAP2 (red). Arrows denote TauCFP exosomes. Scale
bar = 10 μm. Note that TauCFP exosomes were detected in the 2nd order
neurons on the neuritic side, indicating their uptake by 1st order neurons on
the somal side, transport across the microgrooves, and synaptic transmission
to the neurons on the neuritic side. (PNG 157 kb)
Additional file 6: Figure S6. No uptake of sonicated exosomes derived
from N2a cells expressing TauGFP by neurons or astrocytes in organotypic
hippocampal slices. Hippocampal slice cultures were incubated for 24 h
with sonicated exosomes (20 μg) derived from N2a cells expressing
TauGFP. Cultures were then stained for neuronal marker MAP2 (red) and
astrocytic marker GFAP (blue) in hippocampal CA1 region. No TauGFP was
observed in slices. Scale bars in upper panel = 20 μm; in bottom panel = 5 μm.
(PNG 191 kb)
Additional file 7: Figure S7. Nanoparticle tracking analysis of
exosomes isolated from CSF of control (A) and AD subjects (B) showing
particle number vs. size (arbitrary units, peak = 100%). The size
distributions have peaks at diameters of ~85–100 nm (AD) or ~60–90 nm
(non-AD controls). (PNG 29 kb)
Abbreviations
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albumin; CSF: Cerebrospinal fluid; DIV: Days in vitro; EVs: Extracellular vesicles;
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miRNA: MicroRNA; NFTs: Neurofibrillary tangles; NMJ: Neuromuscular
junctions; NTA: Nanoparticle tracking analysis; TauGFP: Human longest isoform
of brain Tau tagged with GFP at the N-terminus; TauRDΔK: Four-repeat domain
of Tau with the mutation ΔK280; TEM: Transmission electron microscopy
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